Andere Sprachen Better Therapeutics, Inc.

Aktien

A3CY5N

US08773T1043

BTTX

Markt geschlossen - OTC Markets Andere Börsenplätze 21:35:30 29.04.2024			% 5 Tage	% 1. Jan.
0,012 ^USD	+20,00 %		+96,72 %	-93,85 %

21.03.	Better Therapeutics, Inc. Erhält Verzugsmitteilung von Hercules Capital, Inc.	CI
14.03.	Sektor-Update: Aktien des Gesundheitswesens am Donnerstagnachmittag niedriger	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	21.03.
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	20.03.
Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from NASDAQ Composite Index	15.03.
Sector Update: Health Care Stocks Lower Thursday Afternoon	14.03.
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	14.03.
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq	14.03.
Better Therapeutics : Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - Form 8-K	14.03.
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers	05.03.
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)	04.03.
Transcript: Better Therapeutics CEO Interview with RedChip - Form 8-K	04.03.
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	20.02.
Better Therapeutics Gets Breakthrough Device Designation For Cognitive Behavioral Therapy Platform	20.02.
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20.02.
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	20.02.
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment	06.02.
Better Therapeutics, Inc. announced that it has received $0.25 million in funding	23.01.
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone	17.01.
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	17.01.
Better Therapeutics, Inc. announced that it expects to receive $0.25 million in funding	05.01.
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Better Therapeutics, Inc.

Aktien

A3CY5N

US08773T1043

BTTX

Andere Sprachen

Filter